$1.15
Live
0.0%
Downside
Day's Volatility :5.74%
Upside
5.74%
13.04%
Downside
52 Weeks Volatility :42.86%
Upside
34.29%
Period | Artelo Biosciences Inc | Index (Russel 2000) |
---|---|---|
3 Months | -17.27% | 0.0% |
6 Months | -11.57% | 0.0% |
1 Year | -21.07% | 0.0% |
3 Years | -89.78% | -23.0% |
Market Capitalization | 3.8M |
Book Value | $2.26 |
Earnings Per Share (EPS) | -3.35 |
Wall Street Target Price | 14.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -54.33% |
Return On Equity TTM | -88.58% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -7.4M |
Diluted Eps TTM | -3.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.58 |
EPS Estimate Next Year | -0.88 |
EPS Estimate Current Quarter | -0.85 |
EPS Estimate Next Quarter | -0.55 |
What analysts predicted
Upside of 1117.39%
Sell
Neutral
Buy
Artelo Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Artelo Biosciences Inc | 5.5% | -11.57% | -21.07% | -89.78% | -96.87% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Artelo Biosciences Inc | NA | NA | NA | -2.58 | -0.89 | -0.54 | NA | 2.26 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Artelo Biosciences Inc | Buy | $3.8M | -96.87% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Artelo Biosciences Inc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 102.4%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 134.6%
Geode Capital Management, LLC
Tower Research Capital LLC
artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.
Organization | Artelo Biosciences Inc |
Employees | 5 |
CEO | Mr. Gregory D. Gorgas M.B.A. |
Industry | Catalog/Specialty Distribution |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.15
-3.36%
Invesco Bulletshares 2025 Hi
$1.15
-3.36%
Schwab International Dividend Equity Etf
$1.15
-3.36%
Blockchain Coinvestors Acquisition Corp.
$1.15
-3.36%
Allgiant Travel Company
$1.15
-3.36%
Rogers Corp
$1.15
-3.36%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.15
-3.36%
Iheartmedia
$1.15
-3.36%
Lightpath Technologies Inc
$1.15
-3.36%